AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by investment analysts at Shore Capital in a research report issued on Monday.
Other analysts also recently issued reports about the company. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 5,500 ($75.99) price objective on shares of AstraZeneca in a research report on Friday, February 2nd. Goldman Sachs Group set a GBX 3,800 ($52.50) price objective on AstraZeneca and gave the company a “sell” rating in a research report on Monday, February 5th. Barclays restated a “top pick” rating and issued a GBX 6,300 ($87.04) price objective on shares of AstraZeneca in a research report on Monday, February 5th. Berenberg Bank upped their price objective on AstraZeneca from GBX 5,800 ($80.13) to GBX 6,000 ($82.90) and gave the company a “buy” rating in a research report on Thursday, February 8th. Finally, Citigroup restated a “buy” rating and issued a GBX 6,000 ($82.90) price objective on shares of AstraZeneca in a research report on Wednesday, January 10th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. AstraZeneca has a consensus rating of “Hold” and an average price target of GBX 5,199.70 ($71.84).
Shares of AstraZeneca (LON AZN) traded up GBX 14.50 ($0.20) during trading hours on Monday, hitting GBX 4,800 ($66.32). The stock had a trading volume of 1,664,175 shares, compared to its average volume of 2,300,000. AstraZeneca has a twelve month low of GBX 4,260 ($58.86) and a twelve month high of GBX 5,520 ($76.26). The stock has a market capitalization of $60,790.00 and a P/E ratio of 2,823.53.
TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/03/12/astrazeneca-azn-stock-rating-reaffirmed-by-shore-capital.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.